Generated August 25, 2026 at 8:35 PM ET
· Covers August 25 trading day
· 8 of 185 ready 8-Ks selected
· AI-assisted overview
Today's filings featured a mix of corporate governance, regulatory, and M&A events. Exyn Technologies disclosed CEO resignation following an expense probe, while OSR Holdings appealed a Nasdaq delisting. AstroNova shareholders approved its acquisition by Arcline, and Two Harbors completed its merger with CrossCountry Mortgage. Jazz Pharmaceuticals and Zymeworks announced FDA approval for a HER2+ cancer regimen, triggering a milestone payment. Par Pacific expects proceeds from a Laramie Energy asset sale, and Dominion Energy faces shareholder lawsuits over its merger proxy.
EXYN
Exyn Technologies, Inc.
leadership
negative
materiality 0.85
August 25, 2026, 5:25 PM ET
CEO resigns after $286K personal expenses probe; interim CEO and chairman named
- CEO Brandon Torres Declet resigned Aug 19 after audit found ~$286K personal expenses on company card.
- Separation Agreement: Declet repays expenses, gets no severance or option acceleration.
- COO Benjamin Williams named interim CEO; salary raised from $294K to $355K.
regulatory
negative
materiality 0.85
August 25, 2026, 11:28 AM ET
OSR Health appeals Nasdaq delisting; trading suspension set for Aug 26
- Received Nasdaq Staff Determination for non-compliance with minimum bid price rule (Rule 5550(a)(2)).
- Submitted hearing request on Aug 25, 2026; trading suspension scheduled for Aug 26, 2026.
- Hearing request expected to stay Form 25-NSE filing pending Panel decision.
M&A
positive
materiality 1.00
August 25, 2026, 1:01 PM ET
AstroNova shareholders approve $29.00/share acquisition by Arcline; closing expected Aug 26
- Vote: 5,027,868 for, 4,693 against, 5,467 abstain; more than 99% of votes cast in favor.
- Approximately 64% of outstanding shares voted for; majority of outstanding shares required and met.
- Merger price $29.00 per share in cash; closing expected August 26, 2026.
JAZZ
Jazz Pharmaceuticals plc
regulatory
positive
materiality 0.90
August 25, 2026, 4:06 PM ET
Jazz Pharma gets FDA approval for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma
- FDA approved Ziihera (zanidatamab-hrii) plus Tevimbra (tislelizumab-jsgr) and chemo for all HER2+ GEA (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status.
- Second approval: Ziihera plus chemo for HER2+ IHC 3+ GEA; based on Phase 3 HERIZON-GEA-01 trial.
- Trial showed 35% PFS risk reduction (12.4 vs 8.1 months) and 28% OS risk reduction (26.4 vs 19.2 months) vs trastuzumab plus chemo.
regulatory
positive
materiality 0.90
August 25, 2026, 10:54 AM ET
FDA approves zanidatamab combo for HER2+ GEA; Zymeworks earns $250M milestone
- FDA approval of Ziihera (zanidatamab-hrii) with/without tislelizumab plus chemo in first-line HER2+ GEA triggers $250M milestone from Jazz.
- Zymeworks has now received $650M total upfront and milestone payments from Jazz; remains eligible for up to $1.3B more and 10-20% royalties.
- BeOne collaboration: $81M received to date; up to $144M additional milestones plus up to 19.5% royalties on sales.
TWO
TWO HARBORS INVESTMENT CORP.
M&A
neutral
materiality 1.00
August 25, 2026, 11:12 AM ET
Two Harbors completes $12.00/share merger with CrossCountry Mortgage; delists
- Merger completed Aug 25, 2026: TWO stockholders receive $12.00/share cash plus $0.20326 stub dividend.
- TWO common stock delisted from NYSE; company becomes wholly owned subsidiary of CrossCountry Mortgage.
- Preferred stock to be redeemed at $25.00/share plus dividends; ~$622M aggregate consideration.
PARR
PAR PACIFIC HOLDINGS, INC.
M&A
positive
materiality 0.75
August 25, 2026, 5:26 PM ET
Par Pacific to receive ~$146M from Laramie Energy $485M asset sale
- Laramie Energy, 46%-owned by PARR, agreed to sell substantially all oil and gas assets for $485M cash, with $60M deferred to 5th anniversary.
- PARR expects ~$146M of proceeds (incl. ~$27.5M deferred) plus up to ~$30M in earn-outs, and will exit its Laramie investment.
- Transaction expected to close by end of 2026, subject to regulatory approvals and customary closing conditions.
litigation
negative
materiality 0.60
August 25, 2026, 6:01 AM ET
Dominion Energy faces shareholder lawsuits over NextEra merger proxy; supplements disclosures
- Two complaints filed in N.Y. Sup. Ct. (Scott, Clark) allege proxy statement disclosure deficiencies; company denies merit.
- Demand letters received; Dominion voluntarily supplements proxy with Lazard and BofA valuation analyses.
- Special meeting to vote on merger set for Sept 3, 2026; implied per-share consideration $76.38 (0.8138 exchange ratio + $0.41 cash).